Login

Access type

Forgot your password? Click here

LOGIN
Annulla
Forgot
DMP_ForgotOK Close

REGISTER

If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.

REGISTER
A A A
Contacts
Follow LinkedIn YouTube

www.dompe.com

History

From intuition to the first steps

1853

Gian Antonio Dompé, an enthusiast for the chemico-pharmaceutical sciences, opens a specialty shop in Milan’s Piazza della Scala.

1866

The Austrian monk, Gregor Mendel, publishes his studies of the transmission of inherited characteristics. They were subsequently forgotten for years before being rediscovered at the beginning of the twentieth century.

1885

Louis Pasteur manages to obtain an attenuated vaccine against rabies by selecting viral mutants that had lost their virulence against humans and animals.

1898

Continuing the profession of his father, Onorato Dompé establishes Italo-English Pharmacies on the basis of British standards. Their production of galenic formulations transforms the typical work of a pharmacy: business developed, and a chain of pharmacies is set up in the principal cities of Italy.

1898 - Onorato Dompé

1928

Upon his return to his laboratory after a holiday, Alexander Fleming notices the formation of a white halo in one of his cultures of a bacterium that was then considered the potential cause of influenza. This first sign of penicillin heralded the dawning of the antibiotic era.

1940

Franco Dompé converts the work of his father into an industrial business by founding Dompé Farmaceutici at the site that still houses the Group’s central offices.

1940 - Franco Dompé

Protagonists in the age of DNA

1953

James Watson and Francis Crick identify the “double helix” structure of DNA, for which they will be awarded the Nobel Prize in Physiology or Medicine in 1962.

1966

Har Gobind Khorana and Marshall Nirenberg decipher the language of the genetic code: reading DNA in groups of three bases (triplets). Both will be awarded the Nobel Prize in Physiology or Medicine in 1968.

1976

Sergio Dompé joins the company and personally defines the strategies of the Group. Dompé Farmaceutici invests in research and concentrates on three therapeutic areas: anti-inflammatory, osteo-articular and respiratory.

1978

The first test-tube baby is born in Great Britain.

1980

Charles Weissmann and his team produce the drug interferon from bacteria.

1986

Rita Levi Montalcini receives the Nobel Prize in Physiology or Medicine for her discovery of nerve growth factor (NGF).

1988

Dompé Biotec, a reference centre for biotechnological innovation in Italy and Europe, is founded.

1990

The first official use of gene therapy is made to treat a young girl affected by adenosine deaminase deficiency in the USA. This treatment will be first used in Italy to treat a young boy affected by the same disease.

1993

Dompé’s production site, which is specialised in producing oral, liquid and granular formulations that guarantee national and international supplies of proprietary products, is founded in L’Aquila.

1996

Dolly, the first cloned sheep, is born at Roslin Institute in Edinburgh after the nucleus of an adult mammary gland cell is inserted into an egg cell.

The modern era

2000

The Human Genome Project completes the reading of DNA.

2000

Dompé establishes a biotechnology plant in L’Aquila for the production of recombinant proteins to treat rare diseases.

2001

In the centenary of the Nobel Prize, the American Leland H. Hartwell and the Britons R. Timothy Hunt and Paul M. Nurse receive the Nobel Prize in Physiology or Medicine for discovering key factors in cell cycle regulation.

2005

Biogen Dompé, a joint venture between Biogen Idec and Dompé, is founded in Italy as a company dedicated to research into new treatments for multiple sclerosis with the aim of offering patients innovative biotechnological products with a high therapeutic profile.

2007

Craig Venter and his collaborators create a complete DNA in a test tube, and subsequently make the first transplant of genetic material from one mycoplasma to another of a different species.

2008

Amgen Dompé, a joint venture between Amgen and Dompé, is founded for the development of drugs to be used in oncology and nephrology. In 2014 the partners mutually agreed to conclude the JV.

2008

Science makes it safe to reprogram skin cells so that they become stem cells without using cloning or destroying embryos. Furthermore, advances are made in the gene therapy of Leber’s congenital amaurosis, a severe eye disease.

2009

Dompé creates its Q-rare Division with the aim of offering innovative therapeutic solutions for the treatment of orphan diseases.

2009

Nature publishes a study of the effects of rapamycin, a drug that may represent a long-life elixir by acting on the metabolism.

2010

Dompé acquires the right to develop, produce and market NGF for the treatment of neurotrophic keratitis, a rare eye disease. This is the first therapeutic application of the findings that led to Rita Levi Montalcini being awarded the Nobel Prize in Physiology or Medicine. Dompé also acquires more than 30% of Philogen, a biotech company involved in the development of oncological drugs.

2010

Craig Venter creates “artificial life”: i.e. a cell made using synthetic, laboratory-constructed DNA that is capable of self-replication.

2011

Dompé’s growth continues, and the extension of its biotech plant in L’Aquila increases its research and production potential.

2011

Progress is made in controlling AIDS as a study demonstrates that drugs can reduce the probability of sexually transmitting the disease in 96% of seropositive people.

2012

Research into use of stem cells continues. A study demonstrates that mouse embryonal stem cells allow the birth of animals to surrogate mothers.

2012

New headquarters are opened in Milan, and Dompé completes the acquisition of Anabasis, an Italian company that develops innovative treatments for eye diseases starting from studies on NGF.

2012

A study by researchers of the University of Washington shows that it will be possible to predict the entire genome of a fetus on the basis of a maternal sample and a paternal saliva sample.

2012

A phase III trial designed to evaluate the efficacy of reparixin in improving the efficiency of allogeneic pancreatic islet transplantation is started in Europe and the USA.

2012

Professor Rita Levi Montalcini, one of the most important scientists in modern medicine, dies in Rome at the age of 103 years.

2013

The first international phase I/II clinical trial of the use of recombinant human NGF in the treatment of neurotrophic keratitis gets under way in 37 European centres.

2013

The Nobel Prize in Physiology or Medicine is awarded to James Rothman, Randy Schekman and Thomas Südhof, three biologists who discovered the mechanism regulating the transport of molecules inside cells.

2013

Dompé announces that rhNGF has been designated an orphan drug for the treatment of retinitis pigmentosa by the European Medicines Agency and the USA Food and Drug Administration.

2013

The British Royal Society expects scientific production China will exceed that of the United States by the end of the year, seven years earlier than previously estimated.

2013

A phase II/III trial designed to evaluate the efficacy and safety of reparixin in the autologous transplantation of pancreatic islets is started in the United States.

2014

Fabiola Gianotti becomes the first woman to be selected as General Director in the 60-year history of the European Organisation for Nuclear Research (CERN).

2014

Enrolment conclusion of the Dompé first phase III trial with reparixin in patients undergoing pancreatic islet transplantations.

2014

Genetic engineering expands the genetic alphabet by synthesising an artificial bacterium that has two additional nucleic acids called X and Y. The two new "letters" can be used to create laboratory-made proteins with new amino acids.

2014

Dompé inaugurates his New York subsidiary with the aim of strengthening the company presence in the USA and coordinate the Research&Development of new drugs for the treatment of diseases in the areas of ophthalmology, oncology and organ transplantation.